Marc Pierre Jean Dunoyer

Chief Financial Officer & Executive Director at AstraZeneca Plc

Marc Pierre Jean Dunoyer

Marc Pierre Jean Dunoyer

Chief Financial Officer & Executive Director at AstraZeneca Plc

Career Highlights

AstraZeneca Plc
GlaxoSmithKline KK

RelSci Relationships


Number of Boards






RelSci Relationships are individuals Marc Pierre Jean Dunoyer likely has professional access to. A relationship does not necessarily indicate a personal connection.

Executive Director, Chief Executive Officer at AstraZeneca Plc

Relationship likelihood: Strong

Founder at Aphrae AB

Relationship likelihood: Strong

Chief Executive Officer at Brambles Ltd.

Relationship likelihood: Strong

Director & Head-Biologicals at GlaxoSmithKline KK

Relationship likelihood: Strong

Venture Partner at 4bio Ventures Management Ltd.

Relationship likelihood: Strong

Director at Temasek International (USA) LLC

Relationship likelihood: Strong

Chief Research Officer at Firmenich SA

Relationship likelihood: Strong

Group Finance Director at Old Mutual Group (UK) Ltd.

Relationship likelihood: Strong

Former Chief Executive Officer at Avon Products, Inc.

Relationship likelihood: Strong

President, Best Buy Health at Best Buy Co., Inc.

Relationship likelihood: Strong

Paths to Marc Pierre Jean Dunoyer
Potential Connections via
Relationship Science
Marc Pierre Jean Dunoyer
Chief Financial Officer & Executive Director at AstraZeneca Plc
Bachelor of Law

Paris-Sorbonne University (also known as Paris IV; French: Université Paris-Sorbonne, Paris IV), was a public research university in Paris, France, from 1971 to 2017. Paris IV was one of the inheritors of the Faculty of Humanities of the University of Paris[1] (also known as the Sorbonne), which ceased to exist following student protests in May 1968. As such, it is a successor of the Sorbonne, whose original focus was humanities.[2] It is a member of the Sorbonne University Group and will merge into the Sorbonne University.[3][4] The university enrolls about 24,000 students in 20 departments specializing in arts, humanities and languages, divided in 12 campuses in Paris. Seven of the campuses are situated in the historic Latin Quarter, including the historic Sorbonne university building, and three in the Marais, Malesherbes and Clignancourt respectively. Paris-Sorbonne also houses France's prestigious communication and journalism school, CELSA, located in the Parisian suburb of Neuilly-sur-Seine, maintains about 400 international agreements.


HEC Paris is a private company headquartered in Paris, France. The firm operates business schools.

Career History
President, Asia Pacific & Japan

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

President, Pharmaceuticals Asia Pacific & Japan
2000 - 2010

GlaxoSmithKline KK researches, develops, imports, manufactures and sells toiletry products. The company was founded on August 18, 1928 and is headquartered in Tokyo, Japan

Boards & Committees
Member, Board of Directors
2018 - Current

Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.

2013 - Current

AstraZeneca UK Ltd. manufactures pharmaceutical products. Its products are used to treat cardiovascular diseases, diabetes, and gastrointestinal infections. The company was founded on November 26, 1998 and is headquartered in London, the United Kingdom.

Executive Director, Chief Financial Officer
2013 - Current

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Marc Pierre Jean Dunoyer. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Marc Pierre Jean Dunoyer's profile does not indicate a business or promotional relationship of any kind between RelSci and Marc Pierre Jean Dunoyer.